FORMULATION AND EVALUATION OF SYNTHESIZED QUINAZOLINONE DERIVATIVE FOR COLON SPECIFIC DRUG DELIVERY

ABSTRACTObjective: The current research deals with the formulation and evaluation of synthesized quinazolinone derivative for colon site specific delivery.Methods: The synthesized quinazolinone derivative was enteric coated 5% Eudragit L-100 with by wet granulation method using guar gum, pectin,and guar gum pectin combination as hydrophilic polymer. The prepared matrix tablet was characterized by differential scanning calorimetry andevaluated for different pre-compression and post-compression studies and drug release profiles.Results: All the matrix tablets were within the range of pharmacopeial limits with better flow properties. All the six formulations of matrix tablets haddisintegrated within 5-6 minutes. The optimized formulation selected was F6 formulation combination of guar gum and pectin with 95.79% of drugrelease than compared to the remaining formulation. The optimized matrix tablets followed zero order kinetics with Fickian diffusion.Conclusion: The results proposed that the combination of guar gum and pectin coated tablet with 5% Eudragit L-100 of synthesized quinazolinonederivative is a promising colon site specific delivery.Keywords: Quinazolinone derivative, In vitro drug release, Disintegration time, Guar gum, Pectin, 5% Eudragit L-100, Colon site-specific delivery, Wetgranulation, Compression

DESIGN AND INVITRO CHARACTERIZATION OF METFORMIN LOADED RESEALED ERYTHROCYTES

Objective: Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes. Theobjective of this study was to retard the release of metformin using carrier erythrocyte for getting a parenteral slow release depot formulation.Methods: The study retards the release of metformin by encapsulating in carrier erythrocyte. Endocytosis is the method used for the encapsulationof the drug metformin.Results: The optimized formulation shows 98.34% of drug release within 12 days. From the in vitro release data, zero order kinetic graph shows thebest fit graph. % cell recovered was found to be 73-78% and it suggests that the loading technique was less destructive.Conclusion: The optimized formulation is a perfect carrier for the parenteral slow release depot of metformin.Keywords: Resealed erythrocytes, Cross-linking, Cell recovery, Endocytosis, Slow release depot formulation

FORMULATION AND EVALUATION OF SYNTHESIZED QUINAZOLINONE DERIVATIVE FOR COLON SPECIFIC DRUG DELIVERY

ABSTRACTObjective: The current research deals with the formulation and evaluation of synthesized quinazolinone derivative for colon site specific delivery.Methods: The synthesized quinazolinone derivative was enteric coated 5% Eudragit L-100 with by wet granulation method using guar gum, pectin,and guar gum pectin combination as hydrophilic polymer. The prepared matrix tablet was characterized by differential scanning calorimetry andevaluated for different pre-compression and post-compression studies and drug release profiles.Results: All the matrix tablets were within the range of pharmacopeial limits with better flow properties. All the six formulations of matrix tablets haddisintegrated within 5-6 minutes. The optimized formulation selected was F6 formulation combination of guar gum and pectin with 95.79% of drugrelease than compared to the remaining formulation. The optimized matrix tablets followed zero order kinetics with Fickian diffusion.Conclusion: The results proposed that the combination of guar gum and pectin coated tablet with 5% Eudragit L-100 of synthesized quinazolinonederivative is a promising colon site specific delivery.Keywords: Quinazolinone derivative, In vitro drug release, Disintegration time, Guar gum, Pectin, 5% Eudragit L-100, Colon site-specific delivery, Wetgranulation, Compression.</jats:p

Pros and cons of phospholipid asymmetry in erythrocytes

Phospholipids of erythrocyte are found as bilayer with choline containing phospholipid like phosphatidyl choline and sphingomylein in the outer layer and amine containing phospholipid like phosphatidyl ethanolamine and phosphatidyl serine in the inner layer. This arrangement is known as phospholipid asymmetry. Lipid asymmetry is maintained throughout the entire life span of red blood cell and is disturbed when cells enter into the stage of apoptosis. We here discuss some of the conditions in which phospholipid asymmetry of erythrocyte is maintained and disturbed and the various detection methods to check the distortion phospholipid asymmetry of it

DESIGN AND INVITRO CHARACTERIZATION OF METFORMIN LOADED RESEALED ERYTHROCYTES

 Objective: Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes. The objective of the present study was to retard the release of metformin using carrier erythrocyte for getting a parenteral slow release depot formulation.Methods: The study retards the release of metformin by encapsulating in carier erythrocyte. Endocytosis is the method used for the encapsulation of the drug metormin.Results: The optimized formulation shows 98.34% of drug release within 12 days. From the invitro release data zero order kinetic graph shows the best fit graph.  % cell recovered was found to be 73-78% and it suggests that the loading technique was less destructive.Conclusion: The optimized formulation is a perfect carrier for the parenteral slow release depot of metformin.Keywords: Resealed erythrocytes, cross linking, cell recovery, endocytosis, slow release depot formulation</jats:p